Where is AstraZeneca headquartered?

AstraZeneca's global headquarters is located at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom. The site houses The Discovery Centre (DISC), a purpose-built 722,000-square-foot R&D facility opened in 2021 that consolidates more than 2,500 scientists and business professionals under one roof. The Cambridge Biomedical Campus is one of the world's largest biomedical research clusters, co-located with Addenbrooke's Hospital and the Medical Research Council Laboratory of Molecular Biology — providing AstraZeneca with an exceptional talent pipeline and collaboration ecosystem anchored in structural biology, genomics, and clinical translational research.

London serves as AstraZeneca's UK commercial head office and Board meeting venue. Macclesfield in Cheshire remains the largest UK manufacturing site and is one of the most established pharmaceutical manufacturing campuses in Europe. Additional UK manufacturing operations run from Speke (Liverpool) and Luton. The UK represents AstraZeneca's largest single country by headcount and R&D investment.

In the United States — AstraZeneca's most important revenue market and target of the $50 billion capital commitment through 2030 — the company operates three primary hubs: Wilmington, Delaware (North America Commercial Headquarters, housing oncology and biopharmaceuticals commercial teams); Gaithersburg, Maryland (biologics and vaccines R&D, being substantially expanded); and Kendall Square, Cambridge, Massachusetts (a new advanced R&D centre announced in 2025, adjacent to the Boston biotech cluster). Manufacturing is being added in Rockville (Maryland) and Tarzana (California) for cell therapy, Mount Vernon (Indiana) for continuous manufacturing, and a flagship drug substance facility in Virginia — the company's largest single manufacturing investment worldwide.

In Sweden, the Gothenburg site employs more than 2,600 professionals from 70 countries and supports the full lifecycle of AstraZeneca medicines from discovery through supply. AstraZeneca's technology operations centre in Chennai, India has grown into a major hub for IT, SAP delivery, digital analytics, and AI/ML talent — a cost-effective scale engine for the Axial transformation program. China is AstraZeneca's largest single-country market by revenue outside the US and is served by major commercial offices in Shanghai and Beijing, with ongoing clinical development activity. In total, the company operates 103 locations across more than 100 countries.

For field sales and account-based marketing (ABM) programs targeting AstraZeneca, the buying geography is highly concentrated. Decision-making authority sits in Cambridge (UK), Wilmington/Gaithersburg/Boston (US East Coast), and Gothenburg (Sweden). Life sciences events and executive engagement in these corridors — particularly Boston's biotech conference circuit, Philadelphia/Wilmington pharma summits, and Cambridge/London UK events — reach the highest-density contact clusters.

The $50 billion US manufacturing investment is creating a materially new buying centre in the Mid-Atlantic (Virginia, Maryland) and Midwest (Indiana), where construction, equipment, MES software, and local professional services vendors have genuine greenfield procurement opportunities. These are site-level buying decisions with regional procurement managers, distinct from the centralised enterprise software and digital decisions that remain in Cambridge and Wilmington.

For digital, technology, and AI vendors: the Chennai technology hub and AstraZeneca's Silicon Valley AI partnerships are active pilot-to-production evaluator nodes. Vendors that can demonstrate integration with AWS (the primary cloud), SAP S/4Hana (Axial), and Salesforce Agentforce will face far lower procurement friction than those requiring greenfield stack additions. AstraZeneca's scale means enterprise-wide agreements are managed centrally, so a regional or site-level pilot win requires a central stakeholder champion in Cambridge or Wilmington to convert to an enterprise contract.